AtriCure, Inc. (NASDAQ:ATRC) Receives $52.44 Consensus PT from Brokerages

Shares of AtriCure, Inc. (NASDAQ:ATRC) have received a consensus rating of “Moderate Buy” from the twelve research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $52.4444.

A number of equities analysts have recently issued reports on ATRC shares. Canaccord Genuity Group increased their price objective on shares of AtriCure from $53.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AtriCure in a report on Wednesday. Zacks Research raised AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 6th. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research report on Thursday, October 30th. Finally, JPMorgan Chase & Co. lifted their price target on shares of AtriCure from $42.00 to $48.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th.

Insider Buying and Selling

In other news, insider Justin J. Noznesky sold 5,166 shares of the firm’s stock in a transaction that occurred on Wednesday, November 26th. The stock was sold at an average price of $37.29, for a total value of $192,640.14. Following the transaction, the insider owned 78,798 shares in the company, valued at $2,938,377.42. This trade represents a 6.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Sven Wehrwein sold 4,967 shares of AtriCure stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $38.00, for a total value of $188,746.00. Following the transaction, the director directly owned 34,374 shares in the company, valued at approximately $1,306,212. The trade was a 12.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 18,166 shares of company stock worth $676,378 in the last quarter. Insiders own 3.50% of the company’s stock.

Hedge Funds Weigh In On AtriCure

Several large investors have recently bought and sold shares of ATRC. Ameritas Investment Partners Inc. increased its position in shares of AtriCure by 6.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,941 shares of the medical device company’s stock valued at $162,000 after purchasing an additional 312 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in AtriCure by 6.5% in the third quarter. PNC Financial Services Group Inc. now owns 6,188 shares of the medical device company’s stock worth $218,000 after buying an additional 380 shares in the last quarter. Teacher Retirement System of Texas grew its position in AtriCure by 5.4% during the second quarter. Teacher Retirement System of Texas now owns 7,512 shares of the medical device company’s stock valued at $246,000 after acquiring an additional 385 shares during the last quarter. Scotia Capital Inc. raised its stake in shares of AtriCure by 1.2% during the third quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock worth $1,328,000 after acquiring an additional 457 shares in the last quarter. Finally, First Bank & Trust lifted its holdings in shares of AtriCure by 6.0% in the 4th quarter. First Bank & Trust now owns 8,805 shares of the medical device company’s stock worth $348,000 after acquiring an additional 495 shares during the last quarter. 99.11% of the stock is currently owned by institutional investors.

AtriCure Price Performance

Shares of ATRC opened at $39.07 on Monday. The firm has a market cap of $1.94 billion, a PE ratio of -64.05 and a beta of 1.40. AtriCure has a 52-week low of $28.29 and a 52-week high of $43.18. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.85 and a current ratio of 3.87. The business’s 50 day moving average price is $38.92 and its two-hundred day moving average price is $36.26.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Wednesday, October 29th. The medical device company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.10. The company had revenue of $134.27 million during the quarter, compared to analyst estimates of $131.25 million. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.54%. AtriCure’s revenue for the quarter was up 15.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.17) EPS. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. On average, equities analysts anticipate that AtriCure will post -0.6 EPS for the current year.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.